nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

01.06.2012 | Original Paper

How close is evidence to truth in evidence-based treatment of mental disorders?

verfasst von: Hans-Jürgen Möller

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Given the importance of the term ‘evidence’ in evidence-based medicine (EBM), the meaning of this term is evaluated, going back to the philosophical tradition and current meaning of the terms ‘evidence’ and ‘truth’. Based on this, current problems in the definition of evidence and in the grading of evidence in EBM are described, taking examples from the field of psychiatry and especially pharmacopsychiatry. These problems underline that the use of the term evidence in EBM is inconsistent and inconclusive. This should be fairly stated in all EBM-related publications, especially in EBM-based guidelines, to avoid severe misunderstandings in and outside the field of psychiatry. Although EBM might have increased empirically driven rational decision-making in psychiatry/medicine, the current limitations should be carefully considered.

American Psychiatric Association APA Guideline Development Process (2006) http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm.Anonymous

Antes G (2004) The evidence base of clinical practice guidelines, health technology assessments and patient information as a basis for clinical decision-making. Z Ärztl Fortbild Qualitätssich 98:180–184PubMed

Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D et al (2004) Grading quality of evidence and strength of recommendations. BMJ 19:1490

Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller HJ (2003) Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 253:22–28PubMedCrossRef

Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Zohar J, Hollander E, Kasper S, Moller HJ, Bandelow B et al (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry 9:248–312PubMedCrossRef

Bandelow B, Zohar J, Kasper S, Möller HJ (2008) How to grade categories of evidence. World J Biol Psychiatry 9:242–247PubMedCrossRef

Bateman A, Fonagy P (1999) Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 156:1563–1569PubMed

Bauer M, Whybrow PC, Angst J (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 3:69–86PubMedCrossRef

Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Unipolar Depressive Disorders (2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8:67–104PubMedCrossRef

10.

Bauer M, Tharmanathan P, Volz HP, Möller HJ, Freemantle N (2009) The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 259(3):172–185

11.

Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5–43

12.

Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR (2008) Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. Br J Psychiatry 192(1):5–11

13.

Bottlender R, Rudolf D, Strauss A, Moller HJ (1998) Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression. Eur Psychiatry 248:296–300

14.

Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, Tyrer P (2000) Framework for design and evaluation of complex interventions to improve health. BMJ 321:694–696PubMedCrossRef

15.

Carnap R (1956) The methodological character of theoretical concepts. In: Feigl HSM (ed) Minnesota studies on the philosophy of science. 1. Minneapolis, pp 38–76

16.

Carnap R (1966) Philosophical foundations on physics. Gardner M, New York

17.

Carpenter WT (2001) Evidence-based treatment for first-episode Schizophrenia? Am J Psychiatry 158:1771–1773PubMedCrossRef

18.

Cartabellotta A, Minella C, Bevilacqua L, Caltagirone P (1998) Evidence-based medicine. 3. Systematic reviews: a tool for clinical practice, permanent education and health policy decisions. Italian Group on Evidence-Based Medicine-GIMBE. Recenti Prog Med 89:329–337PubMed

19.

Cartabellotta A, Montalto G, Notarbartolo A (1998) Evidence-based medicine. How to use biomedical literature to solve clinical problems. Italian Group on Evidence-Based Medicine-GIMBE. Minerva Med 89:105–115PubMed

20.

Catty J, Burns T, Comas A (2001) Day centres for severe mental illness. Cochrane Database Syst Rev (2):CD001710

21.

Chilvers R, Macdonald GM, Hayes AA (2002) Supported housing for people with severe mental disorders. Cochrane Database Syst Rev (2):CD000453

22.

Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H et al (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758PubMedCrossRef

23.

Clark W, Mucklow J (1998) Gathering and weighing the evidence. In: Panton R, Chapman S (eds) Medicines management. BMJ Books and Pharmaceutical Press, London, pp 59–74

24.

Craig JC, Irwig LM, Stockler MR (2001) Evidence-based medicine: useful tools for decision making. MJA 174:248–253PubMed

25.

Crowther R, Marshall M, Bond G, Huxley P (2003) Vocational rehabilitation for people with severe mental illness (Cochrane Review) [computer program]. The Cochrane Library, Issue 3. Update Software, Oxford

26.

Czekalla J (2006) Kritische Bewertung von Studien und Metaanalysen. Ein Fortbildungsartikel über die wichtigsten Validitätskriterien der Evidence-based Medicine. Psychopharmakotherapie 13:224–230

27.

Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553–564PubMedCrossRef

28.

Deutsche Gesellschaft für Psychiatrie PuN DGPPN, BÄK, KBV, AWMF, AkdÄ B, BApK, DAGSHG, DEGAM, DGPM, DGPs et al (eds) (2009) S3-Leitlinien/Nationale VersorgungsLeitlinie Unipolare Depression. Berlin, Düsseldorf. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde

29.

Eccles M, Grimshaw J, Campbell M, Ramsay C (2003) Research designs for studies evaluating the effectiveness of change and improvement strategies. Qual Saf Health Care 12:47–52PubMedCrossRef

30.

Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ (2006) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 7:5–40PubMedCrossRef

31.

Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia (2005) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6:132–191

32.

Fountoulakis KN, Möller HJ (2011) Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14:405–412PubMedCrossRef

33.

Fritze J, Möller HJ (2001) Design of clinical trials of antidepressants. Should a placebo control arm be included? CNS Drugs 15:755–764PubMedCrossRef

34.

Geddes JR, Calabrese JR, Goodwin GM (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194:4–9PubMedCrossRef

35.

Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661PubMedCrossRef

36.

Gerson S, Belin TR, Kaufman A, Mintz J, Jarvik L (1999) Pharmacological and psychological treatments for depressed older patients: a meta-analysis and overview of recent findings. Harv Rev Psychiatry 7:1–28PubMed

37.

Gonzalez DD (2001) From evidence-based medicine to medicine-based evidence. An Esp Pediatr 55:429–439

38.

Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Möller HJ (2002) World Federation of Societies of Biological Psychiary (WFSBP) guidelines for biological treatment of bipolar disorders, Part I: Treatment of bipolar depression. World J Biol Psychiatry 3:115–124PubMedCrossRef

39.

Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, Vieta E, Moller HJ (2003) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, Part II: Treatment of mania. World J Biol Psychiatry 4:5–13PubMedCrossRef

40.

Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ (2004) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, Part III: Maintenance treatment. World J Biol Psychiatry 5:120–135PubMedCrossRef

41.

Grunze H, Vieta E, Guy M, Goodwin GM, Bowden C, Licht RW, Möller HJ, Kasper S, WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2009) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the Treatment of Acute Mania. World J Biol Psychiatry 10(2):85–116

42.

Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schunemann H (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 129:174–181PubMedCrossRef

43.

Hegerl U, Hautzinger M, Mergl R, Kohnen R, Schutze M, Scheunemann W, Allgaier AK, Coyne J, Henkel V (2010) Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients’ choice arm. Int J Neuropsychopharmacol 13:31–44PubMedCrossRef

44.

Hegerl U, Plattner A, Moller HJ (2004) Should combined pharmaco- and psychotherapy be offered to depressed patients? A qualitative review of randomized clinical trials from the 1990s. Eur Arch Psychiatry Clin Neurosci 254:99–107PubMedCrossRef

45.

Horder J, Matthews P, Waldmann R (2010) Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacol [Epub ahead of print]

46.

Huf W, Kalcher K, Pail G, Friedrich ME, Filzmoser P, Kasper S (2011) Meta-analysis: fact or fiction? How to interpret meta-analyses. World J Biol Psychiatry 12:188–200PubMedCrossRef

47.

Jadad AR, Phil D, Cook DJ (1998) Methodology and reports of systematic reviews and meta-analyses-a comparison of cochrane reviews with articles published in paper-based Journals. JAMA 280:278–280PubMedCrossRef

48.

Kallert TW (2005) Is mental health services research in need of randomised controlled trials? Psychiatr Prax 32:375–377PubMedCrossRef

49.

Kawamura T, Tamakoshi A, Wakai K, Ohno Y (1999) Evidence-based medicine and ‘The Cochrane Collaboration’. Nippon Koshu Eisei Zasshi 46:498–506PubMed

50.

Khan KS, Kunz R, Kleijnen J, Antes G (2004) Systematische Übersichten und Meta-Analysen. Ein Handbuch für Ärzte in Klinik und Praxis sowie Experten im Gesundheitswesen. Springer, Berlin

51.

Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 5:e45PubMedCrossRef

52.

Klein DF (2000) Flawed meta-analyses comparing psychotherapy with pharmacotherapy. Am J Psychiatry 157:1204–1211PubMedCrossRef

53.

Koller M, Lorenz W, Abel U (2006) Methodenvielfalt in der klinischen Forschung. MMW-Fortschritte der Medizin 148:85–91

54.

Leichsenring F, Rabung S, Leibing E (2004) The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 61:1208–1216PubMedCrossRef

55.

Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14(4):429–447

56.

Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, Thase ME, Keller MB (2005) Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 30:445–460PubMedCrossRef

57.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223PubMedCrossRef

58.

Linden M (2002) Verhaltenstherapie: theoretische und empirische Grundlagen sowie klinische Anwendungsprinzipien. In: Möller HJ, Laux G, Kapfhammer HP (eds) Psychiatrie and psychotherapie. Springer, Berlin, pp 681–710

59.

Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N (2006) Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 63:757–766PubMedCrossRef

60.

Lohr KN (2004) Rating the strength of scientific evidence: relevance for quality improvement programs. Int J Qual Health Care 16:9–18PubMedCrossRef

61.

Maier W, Möller HJ (2005) Metaanalyses—highest level of empirical evidence? Eur Arch Psychiatry Clin Neurosci 255:369–370PubMedCrossRef

62.

Maier W, Möller HJ (2010) Meta-analyses: a method to maximise the evidence from clinical studies? Eur Arch Psychiatry Clin Neurosci 260:17–23PubMedCrossRef

63.

Manser R, Walters EH (2001) What is evidence-based medicine and the role of the systematic review: the revolution coming your way. Monaldi Arch Chest Dis 56:33–38PubMed

64.

Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiter H, Roberts C, Hill E, Wiersma D (2003) Day hospital versus admission for acute psychiatric disorders. Cochrane Database Syst Rev (1):CD004026

65.

Marshall M, Gray A, Lockwood A, Green R (2003) Case management for people with severe mental disorders (Cochrane Review). The Cochrane Library, Issue 3. Update Software, Oxford

66.

Marshall M, Lockwood A (2003) Assertive communication treatment for people with severe mental disorder (Cochrane Review). The Cochrane Library, Issue 3. Update Software, Oxford

67.

Mittelstraß JH (2004) Evidenz. In: Mittelstraß J (ed) Enzyklopädie Philosophie und Wissenschaftstheorie. Sonderausgabe ed. J. B.Metzler, Stuttgart, pp 609–610

68.

Mittelstraß JH (2004) Wahrheit. In: Mittelstraß J (ed) Enzyklopädie Philosophie und Wissenschaftstheorie. Sonderausgabe ed. J. B.Metzler, Stuttgart, pp 582–587

69.

Mittelstraß JH (2004) Wahrheitsähnlichkeit. In: Mittelstraß J (ed) Enzyklopädie philosophie und wissenschaftstheorie. Sonderausgabe ed. J. B.Metzler, Stuttgart, pp 588–589

70.

Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896–1900PubMedCrossRef

71.

Möller HJ (1976) Methodische Grundprobleme der Psychiatrie. Kohlhammer, Stuttgart

72.

Möller HJ (1978) Psychoanalyse. Erklärende Wissenschaft oder Deutungskunst? Zur Grundlagendiskussion in der Psychowissenschaft. Fink, München

73.

Möller HJ (2001) Methodological issues in psychiatry: psychiatry as an empirical science. World J Biol Psychiatry 2:38–47PubMedCrossRef

74.

Möller HJ (2006) Methodik empirischer Forschung und evidenz-basierter Medizin in der Psychiatrie. In: Möller HJ, Laux G, Kapfhammer HP (eds) Psychiatrie und psychotherapie. 3 Aufl. Springer, Berlin

75.

Möller HJ (2008) Do effectiveness (“real world”) studies on antipsychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci 258:257–270PubMedCrossRef

76.

Möller HJ (2008) Isn’t the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258:451–455PubMedCrossRef

77.

Möller HJ (2009) Is evidence sufficient for evidence-based medicine? Eur Arch Psychiatry Clin Neurosci 259(Suppl 2):S167–S172

78.

Möller HJ, Broich K (2010) Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. Eur Arch Psychiatry Clin Neurosci 260:3–16PubMedCrossRef

79.

Möller HJ, Fuger J, Kasper S (1993) Statistische metaanalyse der Wirksamkeit neuerer Antidepressiva. Antidepressiva und Phasenprophylaktika. Riederer P, Laux G, and Pöldinger W. Neuro-Psychopharmaka.Wien, Springer, pp 252–256

80.

Möller HJ, Maier W (2010) Evidence-based medicine in psychotherapy: possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci 260:25–39PubMedCrossRef

81.

Montgomery SA, Möller HJ (2009) Is the significant superiority of escitalopram compared with other antidepressants cliniclly relevant? Int Clin Psychopharmacol 24:111–118PubMedCrossRef

82.

Neumann PJ, Tunis SR (2010) Medicare and medical technology–the growing demand for relevant outcomes. N Engl J Med 362:377–379PubMedCrossRef

83.

Pilling S, Price K (2006) Developing and implementing clinical guidelines: lessons from the NICE schizophrenia guideline. Epidemiol Psichiatr Soc 15:109–116PubMed

84.

Popper K (1963) Conjectures and refutations. The growth of scientific knowledge. Routledge & Kegan Paul, London

85.

Riedel M, Strassnig N, Müller N, Zwack P, Möller HJ (2005) How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? Eur Arch Psychiatry Clin Neurosci 255:143–148PubMedCrossRef

86.

Sackett DL (2000) Evidence-Based Medicine: How to practice and teach EBM. Churchill Livingstone, New York

87.

Sackett DL, Richardson S, Rosenberg WS, Haynes W, Dt. Ausg: Kunz R, Fritsche L (1999) Evidenzbasierte Medizin. Zuckschwerdt, München

88.

Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. BMJ 312:71–72PubMedCrossRef

89.

Saha S, Coffman DD, Smits AK (2010) Giving teeth to comparative-effectiveness research—the Oregon experience. N Engl J Med 362:e18PubMedCrossRef

90.

Schmacke N (2006) Evidenzbasierte Medizin und Psychotherapie: die Frage nach den angemessenen Erkenntnismethoden. Psychother Psychosom Med Psychol 56:202–209PubMedCrossRef

91.

Schöchlin C, Möller HJ, Engel RR (2002) Meta-Analysen von Antidepressiva-Studien. In: Riederer P, Laux G, Pöldinger W (eds) Neuro-psychopharmaka, Bd. 3, 2. Aufl. Springer, Wien New York, pp 349–363

92.

Seemüller F, Möller HJ, Obermeier M, Adli M, Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W et al (2010) Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials. J Clin Psychiatry 71:1426–1433CrossRef

93.

Stegmüller W (1954) Metaphysik, Wissenschaft, Skepsis. Frankfurt, Wien

94.

Tarski A (1935) Der Wahrheitsbegriff in den formalisierten Sprachen. Stud Philos 1:262–405

95.

Wampold BE, Minami T, Baskin TW, Callen TS (2002) A meta-(re)analysis of the effects of cognitive therapy versus ‘other therapies’ for depression. J Affect Disord 68:159–165PubMedCrossRef

Titel: How close is evidence to truth in evidence-based treatment of mental disorders?
verfasst von: Hans-Jürgen Möller
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 4/2012
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-011-0273-8

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study

White matter abnormalities and their impact on attentional performance in adult attention-deficit/hyperactivity disorder

Depression is associated with low levels of 25-hydroxyvitamin D among Jordanian adults: results from a national population survey

Sensitivity to changes during antidepressant treatment: a comparison of unidimensional subscales of the Inventory of Depressive Symptomatology (IDS-C) and the Hamilton Depression Rating Scale (HAMD) in patients with mild major, minor or subsyndromal depression